Publications

In vitro activity of gemifloxacin (GEMI) against 11,311 clinical bacterial isolates collected from the Latin American region, Lead author: Gales AC, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Activity of AZD2563, a new oxazolidinone, tested against Gram-positive cocci collected in Latin American medical (LA) centers in 2001, Lead author: Sader HS, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Proposed Susceptibility Testing Criteria for AZD2563, A Novel Long-Acting Oxazolidinone (OXA), Lead author: Anderegg T, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Spectrum and Potency of a New Peptide Deformylase Inhibitor, NVP-PDF386, Lead author: Jones RN, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Bactericidal Action and Synergy Studies of BAL9141, A Novel Pyrrolidinone-3-ylidenemethyl Cephem, Tested Against Enterococci and Methicillin-Resistant Staphylococci (MRSA), Lead author: Deshpande LM, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Impact of pharmacokinetic (PK) and microbiological variability on the pharmacodynamics of gatifloxacin (GAT) against S. pneumoniae in children, Lead author: Rubino CM, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Initial Descriptions of Linezolid Resistance in Staphylococcus epidermidis and Streptococcus oralis: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Enne V, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Antifungal activity of caspofungin and the new triazoles compared with itraconazole and amphotericin B against 462 recent clinical isolates of Aspergillus and other filamentous fungi, Lead author: Diekema DJ, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Five years of longitudinal global surveillance for Candida spp. infection: Stability of species distribution and fluconazole susceptibility from 1997-2001, Lead author: Diekema DJ, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates, Lead author: Pfaller MA, presented at 42nd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2002, San Diego, California

Carbapenem and Cefepime Activity Tested Against Ceftazidime- and Ceftriaxone-Resistant Enterobacter spp. Isolates From North America, Latin America, Asia-Pacific, and Europe, 1997-2000: Report From the SENTRY Antimicrobial Surveillance Program, Lead author: Mutnick A, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: Report of the 2001 Data from 15 Medical Centers, Lead author: Rhomberg PR, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Potency and Antimicrobial Spectrum Update for Piperacillin/Tazobactam (2000): Emphasis on its Activity Against Resistant Organism Populations and Generally Untested Species Causing Community-Acquired Respiratory Tract Infections, Lead author: Johnson DM, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Comparative Activity of Garenoxacin (BMS 284756), a Novel Desfluoroquinolone, Tested Against 13,704 Isolates From Community-Acquired Respiratory Tract Infections: Results From the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Widespread Distribution of Plasmid-Mediated CMY-2 AmpC Beta-Lactamase in Human E. coli from the United States, Lead author: Gudlaugsson O, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Genotypic Characterization of Carbapenem-non-Susceptible Acinetobacter spp. Isolated in Latin America, Lead author: Gales AC, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Typing Characterization of Streptococcus pneumoniae (Spn) Non-Susceptible to Cefotaxime (CTX) Isolated in Latin American (LA) Medical Centers, Lead author: Castanheira M, presented at 102nd annual American Society for Microbiology General Meeting (ASM), May 19 – 23, 2002, Salt Lake City, Utah

Intermethod agreement and preliminary quality control guidelines for susceptibility testing AZD2563 by disk diffusion and MIC methods, Lead author: Anderegg T, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Validation of commercial dry-form panels (sensititre) for the susceptibility testing of AZD2563 by disk diffusion and MIC methods, Lead author: Jones RN, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Antimicrobial susceptibilities of H. influenzae and M. catarrhalis causing lower respiratory tract infections: SENTRY Antimicrobial Surveillance Program, Europe 2000, Lead author: Loza E, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Tracking Streptococcus pneumoniae isolates with decreased antimicrobial susceptibility by MIC distribution analysis: SENTRY, Europe 19972000, Lead author: Canton R, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

AZD2563, a new oxazolidinone: bactericidal activity and synergy studies with gentamicin and vancomycin against staphylococci and streptococci, Lead author: Jones RN, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

In vitro activity of meropenem, imipenem, piperacillin/tazobactam, ciprofloxacin, amikacin, and cefepime against P. aeruginosa and A. baumannii isolated from Brazilian intensive care units- MYSTIC Study Group (Brazil 2001), Lead author: Mendes C, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Emerging resistances among Proteus mirabilis isolates in Europe: Report from the MYSTIC programme (1997-2001), Lead author: Mutnick A, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Antimicrobial Susceptibility Patterns of Beta-Haemolytic and Viridans Group Streptococci: Report From the SENTRY Antimicrobial Surveillance Program (1997-2000), Lead author: Gordon K, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Epidemiology of antibiotic resistance of bacterial pathogens from intensive care units: the SENTRY surveillance program in Europe 2000Europe: Update from SENTRY surveillance program 2000, Lead author: Rodriguez-Villalobos H, presented at 12th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 24-27, 2002, Milan, Italy

Importance of Salmonella Causing Bloodstream Infections in Latin America: Report from the SENTRY Antimicrobial Surveillance Program (1997-2000), Lead author: Gales AC, presented at 10th annual International Congress on Infectious Diseases (ICID), March 11 – 14, 2002, Singapore

Antimicrobial Susceptibility of Streptococcus pneumoniae in Latin America: Results from Four Years of the SENTRY Program, Lead author: Sader HS, presented at 10th annual International Congress on Infectious Diseases (ICID), March 11 – 14, 2002, Singapore

Oral Antimicrobial Susceptibility Patterns of Urinary Tract Infection (UTI) Isolates from Hospitalized Patients in Europe (EU), Latin America (LA), and North America (NA): Report from the SENTRY Antimicrobial Surveillance Program (2000), Lead author: Gordon K, presented at 10th annual International Congress on Infectious Diseases (ICID), March 11 – 14, 2002, Singapore

Recent Trends in Resistance Among S. pneumoniae Isolates Worldwide Including an In Vitro Evaluation of BMS284756: Report from the SENTRY Antimicrobial Surveillance Program, 1999-2000, Lead author: Biedenbach DJ, presented at 10th annual International Congress on Infectious Diseases (ICID), March 11 – 14, 2002, Singapore

Susceptibility Trends of H. influenzae (HI) and M. catarrhalis (MCAT) Including Screening of BMS284756 (BMS) Potency: Report from the SENTRY Antimicrobial Surveillance Program, 1999-2000, Lead author: Johnson DM, presented at 10th annual International Congress on Infectious Diseases (ICID), March 11 – 14, 2002, Singapore

Resistance Among the Most Frequent Pathogens Causing Urinary Tract Infections in Hospitalized Patients Compared to Resistance in the Same Species Isolated from Blood Stream Infections: Report from the SENTRY Antimicrobial Surveillance Program (EU 2000), Lead author: Shah P, presented at 10th annual International Congress on Infectious Diseases (ICID), March 11 – 14, 2002, Singapore

Initial Studies of Resistance Patterns in India: Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program Baseline Results for Multi-Resistant Gram-Negative Bacilli and Endemic Salmonella spp. Isolates, Lead author: Jones RN, presented at 10th annual International Congress on Infectious Diseases (ICID), March 11 – 14, 2002, Singapore

Comparative In Vitro Activity of BMS-284756 (T-3811) against Streptococcus pneumoniae in Latin America: SENTRY Antimicrobial Surveillance Program 1999-2000, Lead author: Sader HS, presented at 10th annual International Congress on Infectious Diseases (ICID), March 11 – 14, 2002, Singapore

Summary of MLSB Phenotypes in the Asia-Pacific (APAC), Europe (EU), North (NA) and Latin America (LA): Report from the SENTRY Antimicrobial Surveillance Program (1997-2000), presented at The Sixth Annual annual Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, January 23 – 26, 2002, Bologna, Italy

Antimicrobial Activity of Oxazolidinones (Linezolid) and Streptogramins (Quinupristin/Dalfopristin) Tested Against Nearly 40,000 Gram-Positive Isolates in the Global SENTRY Antimicrobial Surveillance Program (1997-2000), presented at The Sixth Annual annual Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, January 23 – 26, 2002, Bologna, Italy

Linezolid-Resistant Enterococcus faecium Isolated from a Patient Without Prior Exposure to An Oxazolidinone: Case Report from the SENTRY Antimicrobial Surveillance Program, presented at The Sixth Annual annual Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, January 23 – 26, 2002, Bologna, Italy

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. by Pfaller MA, Diekema DJ, Jones RN, Messer SA and Hollis RJ published in J. Clin. Microbiol. 2002; 40 (3): 852-856

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. by Pfaller MA, Messer SA, Hollis RJ and Jones RN published in Antimicrob. Agents Chemother. 2002; 46 (4): 1032-1037

Antimicrobial susceptibility of inducible AmpC β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. by Pfaller MA and Jones RN published in Int. J. Antimicrob. Agents 2002; 19 (5): 383-388

Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: Initial development of in vitro susceptibility test methods. by Jones RN, Pfaller MA, Rhomberg PR and Walter DH. published in J. Clin. Microbiol. 2002; 40 (2): 461-465

In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species. by Jones RN, Biedenbach DJ and Anderegg TR published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 119-122

Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRY Antimicrobial Surveillance Program. by Jones RN, Della-Latta P, Lee LV and Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 137-139

Ciprofloxacin as broad-spectrum empiric therapy–are fluoroquinolones still viable monotherapeutic agents compared with β-lactams: Data from the MYSTIC Program (US) by Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2002; 42 (3): 213-215

BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Programme (2000). by Gordon KA, Pfaller MA and Jones RN. published in J. Antimicrob. Chemother. 2002; 49 (5): 851-855

Antimicrobial resistance in Gram-negative isolates from European intensive care units: Data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme. by Garcia-Rodriguez JA and Jones RN published in J. Chemother. 2002; 14 (1): 25-32

Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): Correlations of results from disk diffusion, Etest and reference dilution methods. by Deshpande LM, Fix AM, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (4): 283-290

Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in Brazil. by Cereda RF, Gales AC, Silbert S, Jones RN and Sader HS published in Infect. Control. Hosp. Epidemiol. 2002; 23 (1): 19-22

Pharmacodynamics in the evaluation of drug regimens. by Bhavnani SM, Ambrose PG and Jones RN published in Ann. Pharmacother. 2002; 36 (3): 530-532

Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: Regional results from SENTRY Antimicrobial Surveillance Program (1998-99). by Bell JM, Turnidge JD, Gales AC, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (3): 193-198